On Wednesday, Panera Bread Co (NASDAQ:PNRA)’s shares inclined 8.17% to $202.27.
Panera Bread Company (PNRA) stated net income of $42 million, or $1.60 per diluted share, for fiscal Q2 2015. Diluted EPS for fiscal Q2 2015 was $1.61 or down 7%, not taking into account charges recorded in fiscal Q2 2015 related to the Company’s formerly declared refranchising initiative of $0.01 per diluted share, and not taking into account the $0.08 per diluted share benefit in fiscal Q2 2014 from a favorable resolution of an insurance coverage matter. The fiscal Q2 2015 results compare to stated net income of $49 million, or $1.82 per diluted share, for fiscal Q2 2014. A reconciliation of GAAP and non-GAAP information is attached to this release as Plan V.
The Company’s fiscal Q2 2015 merged statements of comprehensive income and margin analyses are attached to this release as Plan I. The following table sets forth, for the periods indicated, certain items comprised of in the Company’s merged statements of comprehensive income (in thousands, except per share data and percentages), counting net income and diluted EPS, not taking into account charges related to the Company’s refranchising initiative and the benefit from favorable resolution of an insurance coverage matter, and net income and diluted EPS, as stated:
Panera Bread Company owns, operates, and franchises retail bakery-cafes in the United States and Canada. The company operates through three segments: Bakery-Cafe Operations, Franchise Operations, and Fresh Dough and Other Product Operations. The operates bakery-cafes under the Panera Bread, Saint Louis Bread Co., and Paradise Bakery & Café names that offer fresh baked goods, made-to-order sandwiches, soups, salads, pasta dishes, custom roasted coffees, and other complementary products through on-premise sales, as well as provides catering services.
PPL Corp (NYSE:PPL)’s shares gained 0.26% to $31.30.
PPL Corporation (PPL) will release merged second-quarter 2015 earnings results before the stock market opens on Monday, Aug. 3.
During a conference call with financial analysts that starts at 8:30 a.m. Eastern time, William H. Spence, PPL chairman, president and Chief Executive Officer, and other members of PPL’s executive team will talk about quarterly results and the company’s general business outlook following the spinoff of PPL’s competitive generation business on June 1, 2015.
PPL Corporation, a utility company, delivers electricity and natural gas in the United States and the United Kingdom. It serves 321,000 natural gas and 397,000 electric customers in Louisville and 16 surrounding counties; and 543,000 customers in 77 Kentucky counties and 5 counties in Virginia.
At the end of Wednesday’s trade, Anthem Inc (NYSE:ANTM)‘s shares surged 0.54% to $155.04.
Anthem, Inc. (ANTM) declared that second quarter 2015 net income was $859.1 million, or $3.13 per share. These results comprised of net gains of $0.03 per share. Net income in the second quarter of 2014 was $731.1 million, or $2.56 per share.
Not taking into account the items noted in each period, adjusted net income was $3.10 per share in the second quarter of 2015, an enhance of 21.1 percent contrast with adjusted net income of $2.56 per share in the preceding year quarter (refer to the GAAP reconciliation table for a reconciliation to the most directly comparable measure calculated in accordance with U.S. generally accepted accounting principles, or “GAAP”).
Anthem, Inc., through its auxiliaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small employer, individual, Medicaid, and senior markets.
Agilent Technologies Inc (NYSE:A), ended its Wednesday’s trading session with -0.12% loss, and closed at $40.40.
Agilent Technologies Inc. (A) declared that Dr. Lawrence J. Lesko has received an Agilent Thought Leader Award in support of his research into preclinical toxicological assessments of new medicines.
An internationally recognized pharmacologist, Dr. Lesko directs the Center for Pharmacometrics and Systems Pharmacology at the University of Florida’s College of Pharmacy in Orlando.
Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide. The company’s Life Sciences and Diagnostics segment offers liquid chromatography systems, columns, and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; nuclear magnetic resonance, magnetic resonance imaging, and X-ray diffraction systems; immunohistochemistry; in situ hybridization; hematoxylin and eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation and gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.